Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Richeldi L, du Bois RM, Raghu G
New England Journal of Medicine · 2014
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 1,066 participants. Evidence level: Ia.
循证研究：Nintedanib治疗特发性肺纤维化
Key facts at a glance
- DOI
- 10.1056/NEJMoa1401734
- PMID
- 24836311
- Journal
- New England Journal of Medicine
- Year
- 2014
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 1066
- Intervention
- Nintedanib 150mg BID vs 安慰剂
- Primary outcome
- FVC 年下降率
- Open access
- false
Study Overview
This randomized controlled trial enrolled 1,066 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This randomized controlled trial enrolled 1,066 participants, investigating the effects of Nintedanib 150mg BID vs 安慰剂 on FVC 年下降率.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy